Full Text View
Tabular View
No Study Results Posted
Related Studies
Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study
This study has been completed.
Study NCT00526136   Information provided by Cardiome Pharma
First Received: September 5, 2007   Last Updated: December 17, 2008   History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study
About Study Results Reporting on ClinicalTrials.gov
  Study Status: This study has been completed.
  Study Completion Date: July 2008
  Estimated Primary Completion Date: No date given
No publications provided by Cardiome Pharma

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Torp-Pedersen C, Raev DH, Dickinson G, Butterfield NN, Mangal B, Beatch GN. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion. Circ Arrhythm Electrophysiol. 2011 Oct;4(5):637-43. Epub 2011 Aug 14.




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services